An official website of the United States government
Home
Name
Capivasertib
Alternate Names
Truqap
Abbreviations
None
Category
Chemotherapy
Subcategory
AKT inhibitor
NSC Number
None
Primary Site
Breast
Histology
None
Remarks
November 16, 2023 the FDA approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Coding
This drug should be coded
